Excited to share our latest #ICECAP effort looking at prognostic risk groups amongst 3600 patients treated with RT and long-term ADT for high risk localized prostate cancer now published in European Urology

sciencedirect.com/science/articl…

Reminder: our virtual Sexual Health and Prostate Cancer Group is happening on Wednesday (5/22). See below for information on how to participate:

GU Research Digest for the week of May 11 - 17: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

For #ASCODailyNews , Toni Choueiri, MD, Nazli Dizman, Marc Machaalani & Emre Yekedüz examine recent/ongoing research efforts exploring IO rechallenge after prior ICI exposure to understand its potential in #mRCC : brnw.ch/21wJUtq #GUCSM

Join the Dana-Farber Adult Survivorship team in our Sexual Health and Prostate Cancer Group via Zoom

📅 Wed, May 22nd, 3-4:15pm ET

Open to all Dana-Farber patients with prostate cancer. Email [email protected] for details. #ProstateCancer #SexualHealth

Excited be at the Alliance for Clinical Trials in Oncology Spring meeting! All Colleagues coming together to advance cancer care and research! Dana-Farber Lank Center for Genitourinary Oncology

This free virtual seminar, happening this Friday, includes the presentation 'Living Well as a Prostate Cancer Survivor' by Dr. Alicia Morgans Alicia Morgans, MD, MPH and more from our Brigham and Women's Hospital colleagues as well

GU Research Digest for the week of May 4 - 10: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

Happy #NursesWeek !

Thank you to our the amazing nurses Dana-Farber and in our communities for all that they do.

You rock !

Dana-Farber_GU Dana-FarberNews G O L D I E.

GU Research Digest for the week of April 27 - May 3: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

Congrats to Misha Beltran. Coffey Lecture 2024 at the SUO/SBUR. Fantastic presentation in advanced prostate cancer. Misha Beltran Brigham and Women's Hospital Department of Urology Dana-Farber Lank Center for Genitourinary Oncology Society of Urologic Oncology Society for Basic Urologic Research | SBUR

'Antibody-drug conjugates are a novel way to improve chemotherapy delivery, but their role is still evolving.” Dana-Farber's Brad McGregor, MD, (@BradMcG04), featured in Verywell Health Health on the promise and challenges with these cancer treatments.

➡️ ms.spr.ly/6015YRRgX

PSMAfore sub-analysis shows patients with taxane-naive mCRPC benefit from LuPSMA RLT vs. ARPI change, regardless of prior ARPI. Research presented by Dana-Farber's Xiao Wei, MD, (@xiaoweimd) at #AUA24 plenary session. #ProstateCancer Dana-Farber_GU

➡️ ms.spr.ly/6010YubVr

1/ Now out at Journal of Clinical Oncology! Plasma KIM-1 (pKIM-1) helps predict benign vs malignant renal masses and is prognostic for clinical outcomes.
ascopubs.org/doi/10.1200/JC…

Immunotherapy research in NEJM - For the 1st time in 50 years, results from a phase 3 randomized, placebo-controlled trial show overall survival benefit from adjuvant therapy in patients with kidney cancer. Research by Dana-Farber's Toni Choueiri, MD.

➡️ms.spr.ly/6019Y6WoJ

Oncology Nurse Navigators effectively increased referrals for patients with genitourinary cancer to an exercise program. Jennifer Spencer, RN, presented at #ONSCongress explaining how they overcame barriers through education, assessments, and referrals to the right people.

Can AI help diagnose #cancer ? It can.

Could it also help screen for cancer risk or guide cancer treatment? Possibly.

Our researchers like Eliezer Van Allen, MD are working to safely & effectively advance #AI for cancer diagnostics & prediction.

ms.spr.ly/6013YGKHv